Molecular mechanisms regulating SHBG expression: Implications in Obesity

Cristina Sáez López

Dr. David Martínez Selva Dra. Cristina Hernández Pascual Dr. Rafael Simó Canonge

Laboratory of Diabetes and Metabolism

The work focuses on resolving the clinical problems produced by these pathological situations, with big impact in our society. Obesity has long been associated with these serious health issues, although it has only recently been regarded as a disease in the sense of being a specific target for medical therapy. Developing obesity treatments that target novel pathways is a growing focus for both biopharmaceutical and the medical device industries, because until now there does not exists any secure and effective treatment.

These results have a clear potential application in the pharma industry, as they set the basis for the use of SHBG as a therapy against obesity and its related comorbidities, such as hepatic steatosis. For that reason, we have filed an European patent named "Use of SHBG as a medicament" (EP13382202.3), with a priority date of 30/05/2013. , and currently we are seeking for partners from the industry to license this patent and collaborate in order to fully develop this potential application.

Pharma Industry; Potential Application; SHBG; Therapy; Obesity; Related Comorbidities; Hepatic Steatosis; European Patent; Use of SHBG as a Medicament; EP13382202.3; Priority Date; Partners; License Patent; Collaboration; Develop Potential Application